Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development

Surgery ◽  
2020 ◽  
Author(s):  
Fabio Casciani ◽  
Maxwell T. Trudeau ◽  
Horacio J. Asbun ◽  
Chad G. Ball ◽  
Claudio Bassi ◽  
...  
Pancreatology ◽  
2021 ◽  
Vol 21 ◽  
pp. S103-S104
Author(s):  
F. Casciani ◽  
M. Trudeau ◽  
H. Asbun ◽  
C. Ball ◽  
C. Bassi ◽  
...  

Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 436
Author(s):  
Monika Maria Biernat ◽  
Anna Kolasińska ◽  
Jacek Kwiatkowski ◽  
Donata Urbaniak-Kujda ◽  
Paweł Biernat ◽  
...  

The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48–72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy. Overall survival in those who received convalescent plasma was significantly higher than in the historical group (p = 0.03460). The plasma–treated group also showed a significantly milder course of infection (p = 0.03807), characterized by less severe symptoms and faster recovery (p = 0.00001). In conclusion, we have demonstrated that convalescent plasma is an effective treatment and its early administration leads to clinical improvement, increased viral clearance and longer overall survival in patients with hematological malignancies and COVID-19. To our knowledge, this is the first report to analyze the efficacy of convalescent plasma in a cohort of patients with hematological malignancies.


2015 ◽  
Vol 34 (4) ◽  
pp. S243
Author(s):  
J.C. Grimm ◽  
J. Magruder ◽  
A. Kilic ◽  
V. Valero ◽  
S.P. Dungan ◽  
...  

1998 ◽  
Vol 179 (5) ◽  
pp. 1193-1199 ◽  
Author(s):  
John Hauth ◽  
Baha Sibai ◽  
Steve Caritis ◽  
Peter VanDorsten ◽  
Marshall Lindheimer ◽  
...  

Hematology ◽  
2014 ◽  
Vol 2014 (1) ◽  
pp. 181-189 ◽  
Author(s):  
Sarah Alexander

Abstract For children with acute lymphoblastic leukemia, the identification of those at higher risk of disease recurrence and modifying therapy based on this risk is a critical component to the provision of optimal care. The specific definitions of high-risk ALL vary across cooperative groups, but the themes are consistent, being largely based on leukemia biology and disease response. Intensification of conventional chemotherapy for those with high-risk disease has led to improved outcomes. It is anticipated that the development of rational targeted therapy for specific biologically unique subsets of children with leukemia will contribute to ongoing progress in improving the outcomes for children with acute lymphoblastic anemia.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6517-6517
Author(s):  
William G. Wierda ◽  
Susan Mary O'Brien ◽  
Stefan Faderl ◽  
Alessandra Ferrajoli ◽  
Jan Andreas Burger ◽  
...  

6517 Background: First-line chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) demonstrated improved outcomes, including survival, for fit patients (pts) with CLL. Modifications of this regimen, including intensified rituximab (FCR3), addition of mitoxantrone (FCMR) or addition of alemtuzumab fir high-risk CLL (CFAR), were evaluated but did not improve outcomes in historic comparisons. Methods: We correlated outcomes, including complete remission (CR), time-to-treatment failure (TTF) and overall survival (OS), with new and traditional pretreatment prognostic factors to identify high-risk pts. Results: All pts (N=473) had an NCI-WG indication for treatment and received a first-line FCR-based regimen on trial; the intended treatment was 6 courses. Patient characteristics correlated with outcomes are presented in the table. Factors not associated with outcomes included absolute lymphocyte count; platelet count; performance status; spleen size; liver size; and number of involved lymph node sites. Conclusions: We identified the following as high-risk pretreatment features for patients going on first-line FCR-based therapy: advanced age, presence of 17p del, high B2M (≥4mg/l), and unmutated IGHV gene. Pts with these features should be pursued with new treatment modalities and novel agents in order to improve outcomes. [Table: see text]


Kidney360 ◽  
2021 ◽  
pp. 10.34067/KID.0002322021
Author(s):  
Sami Safadi ◽  
Sarah Murthi ◽  
Kianoush B. Kashani

Early diagnosis of acute kidney injury (AKI) and preventive measures can likely decrease the severity of the injury and improve patient outcomes. Current hemodynamic monitoring variables, including blood pressure, heart and respiratory rates, temperature, and oxygenation status, have been used to identify patients at high risk for AKI. Despite the widespread use of such variables, their ability to accurately and timely detect high-risk patients has been questioned. Therefore, there is a critical need to develop and validate tools that can measure new and more kidney-specific hemodynamic and laboratory variables, potentially assisting with AKI risk stratification, implementing appropriate and timely preventive measures, and hopefully improved outcomes. The new ultrasonography techniques provide novel insights into kidney hemodynamics and potential management and/or therapeutic targets. Contrast-enhanced ultrasonography, Doppler flow patterns of hepatic veins (HV), portal vein (PV), and intra- kidney veins (iKV), and ultrasound elastography are among approaches that may provide such information, particularly related to vascular changes in acute kidney injury, venous volume excess or congestion, and fluid tolerance. This review summarizes the current state of these techniques and their relevance to kidney hemodynamic management.


Sign in / Sign up

Export Citation Format

Share Document